FOR IMMEDIATE RELEASE

NuSep Announces a Significantly improved Full year Financial Results

SYDNEY, AUSTRALIA – 28th August, 2009 – NuSep (ASX: NSP) wishes to announce a significantly improved full year financial results to 30 June 2009. These results reflect improved trading and are ahead of the previously advised numbers.

The highlights are:

- **Revenue up 26%** to $2,167,181 (2008 revenue of $1,714,275)
- **Gross profit up 626%** to $928,708 (2008 gross profit of $127,905)
- **Net loss down 50%** to $2,739,043 (2008 loss of $5,496,190)
- **Operational loss down 94%** for the period to $647,450 (2008 operational loss of $4,134,641)

The increased manufacturing efficiencies achieved over the last year have significantly reduced the Company's overall loss in the 2008/09 year by over 50%. In addition by moving to the Lane Cove facility in Sydney, the Company will save a further $1.3m pa in rental and building related costs. The Company is firmly set to achieve the projected $500,000 profit the 2009/10 financial year.

The critical factors have been the increased sales and ability to significantly improve the Gel manufacturing pass rate, turning this into a profitable division. Sales continue to increase as the Company increases its US market share. NuSep estimates that it currently holds 6% of the US Gels market and plans to grow its share of the US market to 10% over the next 18 months.

Over this last year NuSep has moved from a primarily R&D company into the commercial phase of its development. As part of this development the Company has also established a solid distribution network of direct and OEM sales channels. NuSep uses its direct sales efforts to build brand awareness at a higher margin while the OEM distribution channels generate significant reach, but at lower margins. Over the last year the Company has used the direct sales approach to sell the MF10. This has provided critical customer feedback while building the NuSep brand name. This MF10 'missionary selling' has also generated OEM interest in the MF10 and new products for NuSep to consider acquiring. This is something that NuSep will evaluate over the next 12 months.

NuSep Ltd
324 Burns Bay Rd
Lane Cove NSW 2066

Postal Address
P.O. Box 823
Lane Cove NSW 1595

Contact Details
Telephone +61 2 9420 8384
Facsimile +61 2 9427 8614

Email info@nusep.com
Web www.nusep.com
ABN 33 120 047 556

The Company is currently undertaking a share purchase offer (SPO) to raise $2m. This SPO closes on Friday 4 September 2009 and is underwritten by Directors and Shareholders to $1m. Funds raised under this SPO will be used to strengthen the Balance Sheet.

Attached is the Appendix 4E for 30 June 2009.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world's first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep's world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

- **Gels** – NuSep manufactures and sells precast gels including the innovative iGels, with a 2 year shelf life.
- **Separation Instruments** – NuSep has developed two unique biological separation instruments. The first instrument released in 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument separates sperm for fertility treatments such as IVF and is presently undergoing clinical trials.
- **Biological Products** – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company's website www.NuSep.com

Contact:
Prakash Patel
Chief Financial Officer & Company Secretary
+61 2 9420 8384
prakash.patel@nusep.com

Appendix 4E

Preliminary final report

Name of entity

NuSep Ltd

ABN or equivalent company reference	Financial year ended ('current period')
33 120 047 556	30 JUNE 2009

For announcement to the market

				$A'000
Revenues from ordinary activities	Up	26%	to	2,167
Gross Profit Margin	Up	626%	to	929
Loss from ordinary activities after tax attributable to members	Down	50%	to	(2,739)
Net loss for the period attributable to members	Down	50%	to	(2,739)

Dividends (distributions)	Amount per security	Franked amount per security
Final dividend	Nil	Nil
Previous corresponding period	Nil	Nil

Record date for determining entitlements to the dividend, N/A

Brief explanation of any of the figures reported above (see Note 1) and short details of any bonus or cash issue or other item(s) of importance not previously released to the market:

Refer attached press release.

Consolidated Income Statement

		For the year ended 30 June 2009 $	For the year ended 30 June 2008 $
1.1	Revenues		
	Revenue from sales or services	2,048,229	1,610,892
	Cost of Sales	(1,119,521)	(1,482,987)
	Gross Profit Margin	**928,708**	**127,905**
	Other Income	118,952	103,383
	Marketing	(972,078)	(1,010,770)
	General & administration	(1,067,604)	(1,295,902)
	Research & development	-	(2,520,465)
	Rent, lease surrender & related fixed assets write off	(1,548,912)	(808,209)
	Finance cost expenses	(198,109)	(92,132)
	Total Expenses	(3,786,703)	(5,727,478)
1.2	**Loss before income tax**	**(2,739,043)**	**(5,496,190)**
1.3	Income tax	-	-
1.4	**Loss after income tax from operations**	**(2,739,043)**	**(5,496,190)**
1.5	**Net loss for the period**	**(2,739,043)**	**(5,496,190)**

Consolidated retained profits

		30 June 2009 $	30 June 2008 $
1.7	Accumulated losses at the beginning of the financial period	(10,443,418)	(4,947,228)
1.8	Adjustment relating to AASB 121 9 (and refer to note 11)	215,528	-
	Restated balance at 30 June 2008	(10,227,890)	(4,947,228)
1.9	Net loss attributable to members (*item 1.5*)	(2,739,043)	(5,496,190)
2.0	**Accumulated losses at end of financial period**	**(12,966,933)**	**(10,443,418)**

Consolidated Balance Sheet

		As at 30 June 2009 $	As at 30 June 2008 $
	Current assets		
2.1	Cash and cash equivalents	33,403	695,560
2.2	Trade and other receivables	864,150	444,971
2.3	Inventories	292,737	374,491
2.4	Other assets	38,874	32,886
2.5	**Total current assets**	**1,229,164**	**1,547,908**
	Non-current assets		
2.6	Cash and cash equivalents	-	867,286
2.7	Property, plant and equipment	1,686,736	1,785,590
2.8	Intangible assets	1,985,696	-
2.9	Financial assets	800,000	855,000
2.10	**Total non-current assets**	**4,472,432**	**3,507,876**
2.11	**Total assets**	**5,701,596**	**5,055,784**
	Current liabilities		
2.12	Trade payables	1,857,729	1,136,528
2.13	Other Non Trade Liabilities	1,020,726	1,171,799
2.14	Other payables & provisions	1,654,702	406,994
2.15	**Total current liabilities**	**4,533,157**	**2,715,321**
	Non-current liabilities		
2.16	Other Liabilities	1,553,155	1,192,788
2.17	Long-term provisions	68,755	46,318
2.18	**Total non-current liabilities**	**1,621,910**	**1,239,106**
2.19	**Total liabilities**	**6,155,067**	**3,954,427**
2.20	**Net assets**	**(453,471)**	**1,101,357**
	Equity		
2.21	Issued Capital	11,021,258	10,602,240
2.22	Reserves	1,492,204	942,535
2.23	Retained losses	(12,966,933)	(10,443,418)
2.24	**Total equity**	**(453,471)**	**1,101,357**

Consolidated Cash Flow Statement

		As at 30 June 2009 $	As at 30 June 2008 $
	Cash flows from operating activities		
3.1	Receipts from customers	1,657,789	1,423,162
3.2	Payments to suppliers and employees	(1,838,835)	(6,040,484)
3.3	Government grants	562,384	555,468
3.4	Interest received	51,093	97,052
3.5	Finance costs	(24,395)	(33,245)
3.6	**Net cash flows from/(used in) operating activities**	**408,036**	**(3,998,047)**
	Cash flows from investing activities		
3.7	Payment for purchases of property, plant and equipment	(147,234)	(98,491)
3.8	Payment for purchases of other non-current assets	(1,985,696)	-
3.9	Proceeds from sale of property, plant and equipment	74,191	-
3.10	Proceeds from held-to-maturity investment	867,286	132,714
3.11	**Net cash flows (used in)/from investing activities**	**(1,191,453)**	**34,223**
	Cash flows from financing activities		
3.12	Proceeds from issues of securities	894,917	3,965,022
3.13	Share issue costs	(746,824)	(340,818)
3.14	Proceeds from borrowings	105,425	954,289
3.15	Repayment of borrowings	(132,258)	(127,735)
3.16	**Net cash flows from financing activities**	**121,260**	**4,450,758**
3.17	**Net decrease in cash held**	**(662,157)**	**486,934**
3.18	Cash at beginning of period	695,560	208,626
3.19	**Cash and cash equivalents at end of period** *(see Reconciliation of cash)*	33,403	695,560

Consolidated Statement of Changes in Equity

4.

	Issued Capital $	Foreign currency translation Reserve $	Share options Reserve $	Asset revaluation Reserve $	Accumulated Losses $	Total Equity $
At 1 July 2008	10,602,240	217,358	170,177	555,000	(10,443,418)	1,101,357
Adjustment relating to AASB 121 (and refer to Note 11)	-	(215,528)	-	-	215,528	-
Restated balance at 1 July 2008	10,602,240	1,830	170,177	555,000	(10,227,890)	1,101,357
Movement						
Transaction costs on share issue	(404,839)	-	-	-	-	(404,839)
Currency translation difference	-	(8,806)	-	-	-	(8,806)
Total income and expense for the period recognised directly in equity	10,197,401	(6,976)	170,177	555,000	(10,227,890)	687,712
Loss for the period	-	-	-	-	(2,739,043)	(2,739,043)
Total income and expense for the period	10,197,401	(6,976)	170,177	555,000	(12,966,933)	(2,051,331)
Issue of shares	823,857	-	-	-	-	823,857
Revaluation of investment	-	-	-	(55,000)	-	(55,000)
Revaluation of fixed assets				763,563		763,563
Cost of share based payment	-	-	65,440	-	-	65,440
At 30 June 2009	11,021,258	(6,976)	235,617	1,263,563	(12,966,933)	(453,471)

Reconciliation of cash

Reconciliation of cash at the end of the period (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		30 June 2009 $	30 June 2008 $
5.1	Cash on hand and at bank	33,403	695,560
5.2	**Total cash at end of period** *(item 3.19)*	**33,403**	**695,560**

Other notes to the condensed financial statements

Ratios

		30 June 2009	30 June 2008
6.1	**Loss before tax / revenue** Consolidated loss from ordinary activities before tax (*item 1.2*) as a percentage of revenue (*item 1.1*)	(126 %)	(321 %)

Earnings per security (EPS)

		30 June 2009	30 June 2008
7.1	Basic (losses) per share	(126) cents	(552) cents
7.2	Weighted Average number of ordinary shares used as the denominator in calculating basic earnings per share	2,173,401	956,687
7.3	Diluted (losses) per share	(126) cents	(552) cents

NTA backing

		30 June 2009	30 June 2008
8.1	Net tangible asset backing per ordinary security	($1.06)	$0.54

Issued and quoted securities at end of current period

Category of securities		Total number *	Number quoted *	Amount paid up per security
9.1	**Ordinary issued securities**	**2,298,907**	2,298,907	*Refer 9.3 below*
9.2	Changes during current period (a) Increases through issues (b) Decreases through returns of capital, buybacks	 241,565 -	 241,565 -	

9.3
Ordinary issued securities

Date	Details	Number of Shares *	$
1 July 2008	Opening balance	2,057,342	10,602,240
	Share issue under share placement/offer	67,500	72,000
	Share issue in lieu of fees	174,065	287,005
	Unalloted shares		464,852
30 June 2009	Closing Balance	**2,298,907**	**11,426,097**
	Less- transaction costs arising on share issues		(404,839)
30 June 2009	Closing Balance		**11,021,258**

* In March 2009, post approval at the EGM, the share capital of the company was consolidated on a 1 for 20 basis. The issued capital of the company reduced from 45,965,467 shares to 2,298,907 shares. The above figures have been adjusted to reflect this consolidation.

Segment Reporting

10.

30 June 2009	**Consumable products** $	**Separations** $	**Corporate & Shared Services** $	**Consolidated** $
Revenue from sales or services	1,535,376	512,853	-	**2,048,229**
Revenues from outside the operating activities:				
Interest	-	-	44,761	**44,761**
Profit on sale of assets	-		74,191	**74,191**
Total segment revenue	1,535,376	512,853	118,952	**2,167,181**
Profit/(Loss) from ordinary activities after income tax expense	127,092	(144,186)	(2,721,949)	**(2,739,043)**
Depreciation and amortisation expense included above	80,599	7,695	320,814	**409,108**
Rent, lease surrender & related fixed asset write off	-	-	1,548,912	**1,548,912**
Segment assets	1,157,172	2,154,420	2,390,004	**5,701,596**
Segment liabilities	475,864	435,606	5,243,597	**6,155,067**

Prior period adjustment
11.

At 30 June 2008 an unrealised foreign exchange loss of $215,528 was incorrectly recognised in the Income Statement. This resulted in the foreign currency translation reserve being overstated by $215,528 and conversely the retained earnings attributable to members of the parent entity was understated by $215,528. This adjustment has resulted in the loss after tax at 30 June 2008 decreasing by $215,528 to $5,280,662. Due to this adjustment, basic and diluted earnings per share at 30 June 2008 have increased from (28.7) cents per share to (27.6) cents per share.

Matters Subsequent To The End Of The Financial Year

Since 30 June 2009 NuSep has:

a) The Company released on 10 August 2009 a prospectus for a Share Purchase Offer to raise up to $2m at an issue price of 20 cents per share.

Annual General Meeting

The annual general meeting will be held as follows:

Place	324 Burns Bay Road, Lane Cove, NSW
Date	Thursday 26th November 2009
Time	10am
Approximate date the annual report will be available	15th October 2009

Compliance statement

1 The report has been prepared in accordance with the Corporation Act 2001, Accounting Standards and Urgent Issues Group Interpretations, and complies with other requirements of the law. Accounting Standards, include Australian equivalents to International Financial Reporting Standards "AIFRS". Compliance with AIFRS ensures that the consolidated financial statements and notes of the consolidated entity comply with International Financial Reporting Standards "IFRS".

2 This report, and the accounts upon which the report is based, use the same accounting policies.

3 This report does give a true and fair view of the matters disclosed.

4 This report is based on accounts that are in the process of being audited. Details of any qualifications will follow immediately they are available.

6 The entity has a formally constituted Audit Committee.

Signed:

Name: John Manusu
Chairman

Date: 28 August 2009